Showing 8941-8950 of 9351 results for "".
- derma e Scar Gel Proves Effective in Clinical Trialhttps://practicaldermatology.com/news/20140502-derma_e_scar_gel_proves_effective_in_clinical_trial/2459247/The results of an independent clinical trial on derma e Scar gel formula proved the formula effective for participants who used the product for an eight-week period. Derma e Scar gel is a naturally therapeutic treatment that is designed to smooth, soften, and decrease the look of
- The XV World Congress on Cancers of the Skin to be Held in Edinburghhttps://practicaldermatology.com/news/20140501-the_xv_world_congress_on_cancers_of_the_skin_to_be_held_in_edinburgh/2459248/The XV World Congress on Cancers of the Skin, co-sponsored by The Skin Cancer Foundation and the British Association of Dermatologists, will be held at the Edinburgh International Conference Centre in Edinburgh, Scotland, September 3-6, 2014. The World Congress provides an opportunity for physic
- Outrun the Sun Marks 10 Years of Sun Safety Education and Melanoma Researchhttps://practicaldermatology.com/news/20140428-outrun_the_sun_marks_10_years_of_sun_safety_education_and_melanoma_research/2459253/Outrun the Sun, Inc. (OTS), a nonprofit organization that has raised more than $1 million in support of skin cancer education and melanoma research, celebrates their 10 year anniversary. OTS was formed by Anita Day, Jonna MacDougall, Marci Reddick and Jennifer Patton Sarno because they h
- XOMA Finalizes Gevokizmab Phase III Clinical Program in Pyoderma Gangrenosumhttps://practicaldermatology.com/news/20140428-xoma_finalizes_gevokizmab_phase_3_clinical_program_in_pyoderma__gangrenosum/2459254/Xoma Corporation finalized the plans for gevokizumab Phase III Program in Pyoderma Gangrenosum (PG). The Phase III Study will include two double-blind placebo-controlled clinical studies with 60 patients who have active PG. Paul Rubin, Senior Vice President,
- Free Drug Samples May Influence Prescribing Habitshttps://practicaldermatology.com/news/20140417-free_drug_samples_may_influence_prescribing_habits/2459266/Results of a study published online on April 16 in JAMA Dermatology found that the availability of free medication samples in dermatology offices appears to change pr
- Dermatology Resident Survey Finds Practice Gaps in Patient Safetyhttps://practicaldermatology.com/news/20140417-dermatology_resident_survey_finds_practice_gaps_in_patient_safety/2459267/A 2012 survey-based study of 142 dermatology residents from 44 US and Canadian residency programs was conducted to identify the source of clinical practices among dermatology residents that affect patient safety and determine the best approach for overcomi
- Presentation: PV-10 decreases Melanoma Cells in Tumors and Boosts T-Cellshttps://practicaldermatology.com/news/20140407-presentation_pv-10_decreases_melanoma_cells_in_tumors_and_boosts_t-cells/2459277/Treatment with Provectus Biopharmaceuticals, Inc.'s PV-10 produces a significant decrease in melanoma cells in tumors 7-14 days after treatment, new data show. The data were presented by researchers at the Moffitt Cancer Center at the American Association for Cancer Research Annual Meeting in Sa
- Image Skincare Releases Vectorize Technology™https://practicaldermatology.com/news/20140401-image_skincare_releases_vectorize_technology/2459287/Vectorize Technology has revolutionized ingredient delivery by enabling up to 100 treatments in a single application. Marc Ronert, M.D., Ph.D., President and Medical Director of Image Skincare said, "Vectorize Technology™ is a game-changer. It will revolutionize the way the world thinks a
- Phase 3 Results for Novartis' Secukinumab Reportedhttps://practicaldermatology.com/news/20140322-phase_3_results_for_novartis_secukinumab_reported/2459300/Results from the Phase III FEATURE and JUNCTURE studies show Novartis' secukinumab (AIN457), a selective interleukin-17A (IL-17A) inhibitor, met both co-primary endpoints at Week 12 based on Psoriasis Area and Severity Index (PASI) 75 and Investigator's Global Assessment modified 2011 (IGA mod 2011)
- XOMA Gains Orphan Drug Designation to Treat Pyoderma Gangrenosumhttps://practicaldermatology.com/news/20140225-xoma_gains_orphan_drug_designation_to_treat_pyoderma_gangrenosum/2459332/The FDA approved XOMA Corporation's IL-1 beta antibody gevokizumab for the treatment of pyoderma gangrenosum (PG) under an orphan drug designation. PG is a rare disorder of expanding, painful skin ulcers, which affects one in about 100,000 people. "Selecting pyoderma gangrenosum as our n